Compare NIC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIC | PRCT |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | NIC | PRCT |
|---|---|---|
| Price | $123.74 | $32.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $155.33 | $51.13 |
| AVG Volume (30 Days) | 126.0K | ★ 1.4M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 18.84 | N/A |
| EPS | ★ 9.34 | N/A |
| Revenue | ★ $375,962,000.00 | $299,907,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | $4.72 | $29.44 |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | 9.68 | ★ 50.07 |
| 52 Week Low | $97.90 | $27.80 |
| 52 Week High | $141.92 | $89.49 |
| Indicator | NIC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 46.15 |
| Support Level | $129.79 | $31.70 |
| Resistance Level | $132.84 | $34.88 |
| Average True Range (ATR) | 3.10 | 1.63 |
| MACD | -0.87 | -0.27 |
| Stochastic Oscillator | 4.99 | 13.00 |
Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.